Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

7.58
-0.0900-1.17%
Pre-market: 7.52-0.0600-0.79%04:42 EDT
Volume:4.33M
Turnover:32.90M
Market Cap:785.16M
PE:-1.45
High:7.88
Open:7.63
Low:7.31
Close:7.67
Loading ...

Bernstein Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
16 hours ago

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Zacks
·
04 Jun

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

Intellia Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
03 Jun

Intellia Therapeutics price target lowered to $54 from $74 at Canaccord

TIPRANKS
·
03 Jun

Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study

TIPRANKS
·
30 May

Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating

TIPRANKS
·
30 May

Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
30 May

Intellia's Stock Drops Following Adverse Event in Nex-Z Trial

Dow Jones
·
29 May

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating

TIPRANKS
·
29 May

Intellia Therapeutics price target lowered to $39 from $43 at BofA

TIPRANKS
·
29 May

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

MT Newswires Live
·
29 May

TD Cowen Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Intellia Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
29 May

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating

MT Newswires Live
·
29 May

J.P. Morgan Remains a Hold on Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (SVRA) and Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Intellia Therapeutics Updates on Phase 3 Study Progress

TIPRANKS
·
29 May

Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating

TIPRANKS
·
21 May